BISPECIFIC FUSION POLYPEPTIDE AND APPLICATION THEREOF
A bispecific fusion polypeptide that binds to vascular endothelial growth factor (VEGF) A and VEGFC is provided, comprising a first domain that specifically recognizes VEGFA and a second domain that specifically recognizes VEGFC. Also provided is a method for treating or preventing diseases related to VEGFA or VEGFC by the described bispecific fusion polypeptide..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 21. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DONG SICONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-03-21, Last update posted on www.tib.eu: 2024-04-29, Last updated: 2024-05-03 |
|---|
| Patentnummer: |
AU2022325360 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003097374 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003097374 | ||
| 003 | DE-627 | ||
| 005 | 20240503111502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003097374 | ||
| 035 | |a (EPA)AU2022325360 | ||
| 035 | |a (EPA)85199831 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a DONG SICONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BISPECIFIC FUSION POLYPEPTIDE AND APPLICATION THEREOF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-03-21, Last update posted on www.tib.eu: 2024-04-29, Last updated: 2024-05-03 | ||
| 520 | |a A bispecific fusion polypeptide that binds to vascular endothelial growth factor (VEGF) A and VEGFC is provided, comprising a first domain that specifically recognizes VEGFA and a second domain that specifically recognizes VEGFC. Also provided is a method for treating or preventing diseases related to VEGFA or VEGFC by the described bispecific fusion polypeptide. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG HUI |e verfasserin |4 aut | |
| 700 | 0 | |a SUN WENJIE |e verfasserin |4 aut | |
| 700 | 0 | |a LIU YI |e verfasserin |4 aut | |
| 700 | 0 | |a FENG YANG |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 21. März |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/85199831/publication/AU2022325360A1?q=AU2022325360 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 | ||